良性前列腺增生和前列腺癌中的血清肝细胞生长因子激活剂（HGFA）
Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
作者信息
Nagakawa Osamu, Yamagishi Toshiya, Fujiuchi Yasuyoshi, Junicho Akira, Akashi Takuya, Nagaike Kazuhiro, Fuse Hideki
机构信息
Department of Urology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan.
出版信息
Eur Urol. 2005 Oct;48(4):686-90. doi: 10.1016/j.eururo.2005.05.020.
OBJECTIVES
Hepatocyte growth factor activator (HGFA) is responsible for proteolytic activation of the precursor form of hepatocyte growth factor (HGF). We attempted to clarify whether serum levels of HGFA could be used as a marker for prostate cancer.
MATERIAL AND METHODS
Serum levels of total HGF and HGFA were measured by enzyme-linked immunosorbent assay in 99 healthy controls, 27 patients with benign prostatic hyperplasia (BPH) and 119 patients with prostate cancer.
RESULTS
: The mean+/-S.D. serum levels of HGFA in untreated prostate cancer and BPH cases were 0.42+/-0.24 and 0.50+/-0.26 ng/ml, respectively (no significant difference). Serum HGFA was significantly elevated in hormone-refractory prostate cancer (stage D3) compared to other stages, while HGF did not significantly differ with regard to clinical stage.
CONCLUSIONS
Serum HGFA tends was elevated in patients with advanced stage prostate cancer. Further studies in large groups of patients are needed to clarify the clinical value of HGFA.
目的
肝细胞生长因子激活剂（HGFA）负责肝细胞生长因子（HGF）前体形式的蛋白水解激活。我们试图阐明血清HGFA水平是否可作为前列腺癌的标志物。
材料与方法
采用酶联免疫吸附测定法测量99名健康对照者、27名良性前列腺增生（BPH）患者和119名前列腺癌患者血清中总HGF和HGFA的水平。
结果
未经治疗的前列腺癌和BPH病例中HGFA的平均±标准差血清水平分别为0.42±0.24和0.50±0.26 ng/ml（无显著差异）。与其他阶段相比，激素难治性前列腺癌（D3期）血清HGFA显著升高，而HGF在临床分期方面无显著差异。
结论
晚期前列腺癌患者血清HGFA往往升高。需要对大量患者进行进一步研究以阐明HGFA的临床价值。
Zotero 插件